Company Overview and News
2018-10-15 globenewswire - 1
George Town, October 15th, 2018 - Endeavour Mining (TSX:EDV) (OTCQX:EDVMF) provides notice that it will release its financial results for the third quarter of 2018 on Wednesday, November 7th, before TSX market open. Management invites you to participate in a conference call and live webcast on the same day at 8:30am (EST) to discuss the Company's financial and operational results.
EDVVF EDVMF EVR EDV
TORONTO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Compass Gold Corp. (TSX-V:CVB) (Compass or the Company) is pleased to provide an update on the now completed priority shallow soil geochemical survey program over the Kourou and Tiélouléna exploration permits on its Sikasso Property in Southern Mali.
COGDF HUMRF EDVVF EDVMF EVR COGDD CVB.H HUM EDV
Abidjan, September 24, 2018 - Endeavour Mining (TSX:EDV)(OTCQX:EDVMF) is pleased announce positive drill results for the Fetekro greenfield exploration property, located in north-central Côte d'Ivoire approximately 500km from Abidjan.
EDVVF BVVBY EDVMF BVINV EVR BVI EDV
TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Barrick Gold Corporation (NYSE:ABX)(TSX:ABX) (“Barrick” or the “Company”) today announced that it has reached agreement on the terms of a recommended share-for-share merger of Barrick and Randgold Resources Limited (the “Merger”).
ANFGY MALRY DTK AU RRS MIN AULGF EDVVF LNSTY AGG MS ABX EDV FISI ABX ANTO RGORF EDVMF FIISO FIISP GOLD GOLD ANFGF 70GD EVR MALRF
In case you missed out on previous editions of this newsletter, simply click here, here or here to catch up.
OCANF EMRRF LUNMF CNL MUN NSU FNLPF TGB THO MUX.RTWI MAG EVM MUNMF MUX SEMFF NEVDF ABX TAHO GPL MUX OKSWF CDEUW BGMZF DRGDF CDE LYDIF NCU OSKGF MAG APR APRLY TKO EXK NEM CPNFD CGOOF LUNCF GSV TECK DGC EDVVF OR TCKRF EDR GG EDV ABX EDVMF DPMLF LUN EVR
George Town, September 4, 2018 - Endeavour Mining (TSX:EDV OTCQX: EDVMF) ("Endeavour") is pleased to announce that it has entered into a binding sale agreement for its interest in the non-core Tabakoto mine to Algom Resources Limited ("Algom"), a subsidiary of BCM Investments Ltd, for a total cash consideration of US$60 million. The consideration is payable upon closing of the transaction which is expected to occur during the fourth quarter of 2018.
EDVVF EDVMF EVR EDV
Predictive Discovery Ltd (ASX:PDI) has started a diamond drilling program, targeting high-grade gold mineralisation at its Kokoumbo Project in Cote d’Ivoire.
RGORF EDVVF EDVMF EVR GOLD RRS PDI EDV GOLD
2018-08-02 seekingalpha - 3
Good morning. My name is Leonie, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Sandstorm Gold Limited Second Quarter Results Conference Call. All lines have been placed on mute to prevent any background noise.
ICG RIO RIO YRI MEAOF NXXGD BTR ICGQF RTPPF MUX.RTWI NXXGF AUY EDVVF RTNTF MUX EDV WPM SAND SSL SDDXF MUX NXS EDVMF SNXZF RGLD RIO EVR RGL
2018-07-16 accesswire - 1
VANCOUVER, BC / ACCESSWIRE / July 16, 2018 / Sandstorm Gold Ltd. ("Sandstorm Gold Royalties,'' "Sandstorm" or the "Company") (NYSE American: SAND; TSX: SSL) is pleased to provide an update related to share repurchases under the Company's Normal Course Issuer Bid ("NCIB"), recent developments from the Company's royalty portfolio, as well as the acquisition of eight royalties on exploration-staged properties.
YRI KGI.DB MALRY MEAOF AU NXXGD MIN AULGF NXXGF AUY EDVVF AGG KL EDV SSL SAND SDDXF KGI NXS KGI.DB.A EDVMF SNXZF EQXGF EVR MALRF ERDCF
Orezone just released an Updated Feasibility Study highlighting their Bomboré project as possessing: strong economics, modest CapEx, quick payback, simple mine plan, and ample remaining development/exploration upside potential.
ORZCF WFRSF BTG WAF EDVVF EDVMF EVR OCR EDV ORE
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ASX:EVR / ENDEAVOUR MINING CORPORATION on message board site Silicon Investor.